Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group - Wikidata - awgldk - TriplyDB

Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group

Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group

http://www.wikidata.org/entity/Q33813608

about

Multimodality Treatment in Ewing's Sarcoma Family Tumors of the Maxilla and Maxillary Sinus: Review of the Literature Children's Oncology Group's 2013 blueprint for research: bone tumors Management of Ewing sarcoma family of tumors: Current scenario and unmet need Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines Formation and Rupture of the Internal Carotid Artery Aneurysm after Multiple Courses of Intensity-Modulated Radiation Therapy for Management of the Skull Base Ewing Sarcoma/PNET: Case Report.Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Molecular pathology of bone tumours: diagnostic implications.Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applications.Primary intracranial Ewing sarcoma with an unusually aggressive course: a case report and review of the literature.R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis Targeted Therapy of Ewing's Sarcoma.New therapeutic targets in soft tissue sarcoma.Bone- and cartilage-forming tumors and ewing sarcoma: an update with a gnathic emphasis.Growth-promoting role of the miR-106a~363 cluster in Ewing sarcoma.Molecular diagnosis in Ewing family tumors: the Rizzoli experience--222 consecutive cases in four years Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.Promiscuous partnerships in Ewing's sarcoma.Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection.Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology Group Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours.The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.Genomic EWS-FLI1 fusion sequences in Ewing sarcoma resemble breakpoint characteristics of immature lymphoid malignancies.A Decade in Banking Ewing Sarcoma: A Report from the Children's Oncology Group.Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.Synthetic treatment of intracranial peripheral primitive neuroectodermal tumor with multiple metastasis: a case report.Ewing sarcoma/peripheral primitive neuroectodermal tumor and related tumors.Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.The diversity of soft tissue tumours with EWSR1 gene rearrangements: a review.Molecular cytogenetic characterization of two established ESFT cell lines.Micro-Environmental Stress Induces Src-Dependent Activation of Invadopodia and Cell Migration in Ewing Sarcoma.Clinical and biological significance of hepatoma-derived growth factor in Ewing's sarcoma.1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma.Pathobiologic markers of the ewing sarcoma family of tumors: state of the art and prediction of behaviour.Primitive neuroectodermal tumor of the liver: a case report.Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group.Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis.A bivalent promoter contributes to stress-induced plasticity of CXCR4 in Ewing sarcoma Antibody detection of translocations in Ewing sarcoma

P2860

Q26740437-3CEDAF48-EA28-4FEA-BE3B-D45A81051785 Q27027664-22D3AEEC-A76F-4DF5-AED3-43395F5348BC Q28073218-21ED6BCC-6E07-4065-9CFB-C3D70E3B9C87 Q28535586-63E0D510-441C-4632-824E-5A2C8D6FD442 Q30446368-0FED52D0-9328-4B73-A398-C3948175DB0E Q33274572-9B2FA31A-F861-4ECD-B575-7C0F744C4DAC Q33275105-521845D6-3B64-4996-9441-D26F2C2DADD0 Q33992622-7694C2A3-ACB2-4F94-A208-B6117D76C831 Q34050631-9CAD6FD6-89BA-40CF-851A-4B5F618F324B Q34055933-DEC2348B-5C5B-423E-80C5-896EE68918C6 Q34262377-E66653C5-3939-4998-8BC7-DF767F2631C8 Q34267924-5031BB08-B8C6-4D8A-9C7C-8E70272BC3EF Q34577384-9B930556-C51B-4728-BAF7-609433C848A3 Q34702270-0EA6EF50-E312-47DB-95BD-A9EDD7ADA5FB Q34801108-E55DD785-EDE2-4000-8D38-EFFBEDF31C5A Q35118454-C255F694-1DAD-41FF-81DA-73C343C54006 Q35188770-B23A84CA-FA68-45C4-A2C9-D8F23C6F698B Q35212670-93AA1F95-C6B1-4556-89B0-04CFF151E9EA Q35607070-F1EC67DF-34A7-429B-B902-035AD1EC1F63 Q35688154-C6593051-963A-430D-BF25-84770BCD1462 Q35957998-550966C4-16D6-4552-AFB8-5F673FBFA45A Q36547737-151CD620-3CCE-486B-B992-48C154A3C07D Q36562726-63B3D7B2-495A-4F56-B121-DC30B01BF9EC Q36618540-70E228F1-F58E-46D8-B269-4716FFBFBE0E Q36700671-C334BF98-E6F9-4979-AE03-CD5994C0C579 Q36907188-05088B44-6E89-4FC4-9171-F1031B3A516A Q36982238-A0812E64-63BF-4108-A4C1-ACB182DF0EFF Q37993924-620DD4FC-BB23-40D7-A9F9-919406A15719 Q38168996-EE2779BB-9192-4FED-AE78-490FE8E3F39C Q38169791-AE99717F-EB88-42CD-8965-849C5744F942 Q38747083-94F5BC4B-5875-4C2C-9E78-F01F57846850 Q38749818-73BF77ED-E381-42EF-8049-3A69A82BA3AA Q39121566-6F0B6A00-1EEE-495A-96C7-DFC9F20462C9 Q39493814-DEDE99CB-A037-4C9C-8A0A-6572869EE6AE Q39823354-8240C195-1C92-44A0-8898-A6D67331525B Q40261262-D321271A-5A2D-4DA3-90E4-85803081F19B Q40702959-DA664292-B769-4174-86F5-A5AEB6DD76B8 Q42106350-820FEE26-F92B-4B70-BB52-6E9978EBF7FB Q42321604-F1A61183-883C-4354-8B47-42A35AD4B65F Q42325685-8C82C941-1CEA-4F07-9DD7-FC9F2E6D0232

P2860

Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group

http://www.wikidata.org/entity/Q33813608

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Current treatment protocols ha ...... the Children's Oncology Group

@ast

Current treatment protocols ha ...... the Children's Oncology Group

@en

type

label

Current treatment protocols ha ...... the Children's Oncology Group

@ast

Current treatment protocols ha ...... the Children's Oncology Group

@en

prefLabel

Current treatment protocols ha ...... the Children's Oncology Group

@ast

Current treatment protocols ha ...... the Children's Oncology Group

@en

P1433

Q33813608-B9DB87FE-2903-4712-BD03-5C78DF8EA64D

P1476

Q33813608-C7DE48A9-766D-4626-8408-76B2B2E6D38C

P2093

Q33813608-17B55359-F570-4067-91CE-2CEFB3F83189

Q33813608-3475A433-97A8-482A-A1E0-096C55EECBEC

Q33813608-453E3684-282C-47D0-A409-1BD8FF7C35C4

Q33813608-47221375-7B20-4EE9-A98D-A55ACD224FAA

Q33813608-49F7F944-3DDB-46BB-A7F6-BFA718CAECB9

Q33813608-5C4DE180-730F-4E79-B2AE-F69E044B0DE6

Q33813608-5D10BAC9-6722-4CDA-96AD-C7E04E376CC9

Q33813608-6777A56F-C6DF-40B8-8A5E-1402F7C5BE96

Q33813608-85BBB924-531B-4618-990A-0762DFBE5870

Q33813608-A6DC8A31-B2FE-4525-8D6E-03CE826979A3

P2860

Q33813608-042326A9-0685-4614-A4CC-044E4465049E

Q33813608-1DB92972-1B64-4936-AD2B-C7D6CDD04CE3

Q33813608-20B28812-B771-4977-960E-81C0C5EB2801

Q33813608-26B6369F-A260-4952-8ADC-642274A2DA5A

Q33813608-372089C7-7F32-43DF-83D9-FD5966C207B6

Q33813608-37DA8D48-0091-45B5-954E-055BBC667DD1

Q33813608-42BDCC31-A237-4F22-9692-C3B7DDCD20BC

Q33813608-4FBC90EE-FAFD-4B68-8295-35EEC1BCFA30

Q33813608-6143B5B5-717F-4B63-8A39-6A7B40F1F1F3

Q33813608-68DB2027-D166-4F76-9059-DFEF3BF08C79

P304

Q33813608-49B2F183-3D93-4A48-A200-7A1B1D15E50F

P31

Q33813608-E5B86738-294A-449A-88A9-097ABD01D561

P356

Q33813608-B6A1880E-6047-4DD5-AB99-06ABC50B4852

P407

Q33813608-84BDE59E-2B16-44F5-98F3-C869C033F765

P433

Q33813608-D8E138C2-92AD-469A-BB54-9AA28BB14B1A

P478

Q33813608-789A5205-8CBF-4C85-8C9C-E658511CA46F

P577

Q33813608-113EE548-F847-4B49-B30D-8683623D4D93

P5875

Q33813608-562F8A43-FA6D-48DF-844F-5702A6F769D3

P698

Q33813608-FE71214E-FC06-49D4-A35D-7F44CFC53947

P932

Q33813608-5D3819E7-8E09-4AB9-9164-0CD9473895CC

P356

JCO.2009.24.5845

P1433

Journal of Clinical Oncology

P1476

Current treatment protocols ha ...... the Children's Oncology Group

@en

P2093

Betty Schaub

http://www.w3.org/2001/XMLSchema#string

Elizabeth R Lawlor

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Shimada

http://www.w3.org/2001/XMLSchema#string

John A van Doorninck

http://www.w3.org/2001/XMLSchema#string

Lingyun Ji

http://www.w3.org/2001/XMLSchema#string

Mark D Krailo

http://www.w3.org/2001/XMLSchema#string

Michele R Wing

http://www.w3.org/2001/XMLSchema#string

Neyssa Marina

http://www.w3.org/2001/XMLSchema#string

Richard B Womer

http://www.w3.org/2001/XMLSchema#string

Richard Sposto

http://www.w3.org/2001/XMLSchema#string

P2860

EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma.

Localised Ewing sarcoma/PNET of bone--prognostic factors and international data comparison.

Treatment of Ewing sarcoma family of tumors: current status and outlook for the future.

Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.

Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis.

Prognostic impact of chromosomal aberrations in Ewing tumours

Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies.

Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.

Small round cell sarcomas.

Combinatorial generation of variable fusion proteins in the Ewing family of tumours.

P304

1989-1994

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.24.5845

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42389654

http://www.w3.org/2001/XMLSchema#string

P698

20308669

http://www.w3.org/2001/XMLSchema#string

P932

2860404

http://www.w3.org/2001/XMLSchema#string